17 alpha-hydroxyprogesterone caproate has been researched along with Retinopathy of Prematurity in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Awwad, J; Ghazeeri, G; Hayek, S; Nassar, AH; Saasouh, W; Succar, J; Usta, IM; Yacoub, N | 1 |
1 trial(s) available for 17 alpha-hydroxyprogesterone caproate and Retinopathy of Prematurity
| Article | Year |
|---|---|
A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Double-Blind Method; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature; Infant, Very Low Birth Weight; Injections, Intramuscular; Odds Ratio; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Pregnancy, Twin; Premature Birth; Progestins; Respiratory Distress Syndrome, Newborn; Retinopathy of Prematurity; Sepsis | 2015 |